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We describe our experience with an apparently immunocompetent child presenting with pyrexia of unknown origin without
focal signs. Investigations revealed lymphadenopathy at lung hila, mesentery, and porta hepatis. The child had received at least
two months of empiric antituberculous therapy (ATT) before she came to us. A CT-guided biopsy revealed granulomatous
inflammation. PAS stain showed yeasts which stained blue with Alcian blue, suggesting C. neoformans.
1. Background
Lymphonodular cryptococcosis has been reported in the past
in immunocompromised and immunocompetent children
[1, 2]. The two species, C. neoformans and C. gattii, enter
the respiratory system through inhalation and disseminate
hematogenously to various sites in the body [3]. Disease
manifestations range from localized disease such as menin-
gitis, pulmonary infiltrates, and lymphadenopathy to dis-
seminated cryptococcosis with multiorgan involvement [3].
Cryptococcosis has classically been associated with acquired
and inherited T-cell deficiencies [4]. Though antiretroviral
therapy has decreased the incidence of cryptococcosis in
HIV patients, it is increasingly being reported in a non-HIV,
nontransplant cohort [5]. The underlying pathophysiology is
not clear. We report the case history of a 5-year-old female
child with Fever of Unknown Origin (FUO) and abdominal
lymphadenopathy. A CT-guided lymph node biopsy showed
granulomatous inflammation and encapsulated yeasts resem-
blingCryptococcus species. Culture was negative for Acid Fast
Bacillus (AFB) and bacterial and fungal cultures could not be
sent due to inadequate tissue sample. The child responded
clinically and serologically to 6 months of oral fluconazole
and remains well to date.
2. Case History
A 5-year-old female child had remained well and thriving
till 10 weeks before presentation when she developed high
grade, continuous fever associated with nonradiating, central
abdominal pain and anorexia. She had started taking three-
drug antituberculous therapy (ATT) (isoniazid, rifampicin,
and pyrazinamide) based on a general practitioner’s pre-
scription/physician discretion due to the clinical finding of
nontender lymphadenopathy and unabated fever for 2 weeks.
The modified Keith Edwards scoring had not been done and
neither had the tissue culture been sought. By week 8 of
empiric ATT for presumed TB adenitis, there was no clinical
improvement and a weight loss of 2.5 kg was observed.
She was the second amongst 3 siblings and a student of
kindergarten. She had a positive BCG scar with immuniza-
tion complete for age as per Pakistan’s Expanded Programme
of Immunization (EPI) schedule. There was no contact
history for tuberculosis (TB), no family pets, or travel beyond
her hometown. She belonged to a middle-income family and
was a resident of a neighbouring city (approximately 160 km
away from Karachi). The father was a civil servant, and the
mother was a housewife.
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Figure 1: H&E stain of mesenteric lymph node biopsy showing
granuloma formation, 400x.
On examination, the child was febrile, icteric, and pale
with hepatomegaly. There was no peripheral adenopathy.
Investigations done prior to presentation in the Infectious
Disease (ID) clinic revealed normochromic, normocytic
anemia (Hb 7.4mg/dL), a progressively rising white count
over twelve weeks of fever (21 × 109/L at outset to 32 × 109/L
at presentation in ID clinic), high inflammatory markers:
Erythrocyte Sedimentation Rate (ESR 135mm/hr) and C-
reactive protein (CRP29), direct hyperbilirubinemia (total
bilirubin 4.6 with 3.7 direct component), and an episode
of E. coli Urinary Tract Infection (UTI), along with lym-
phadenopathy seen at the lung hila (chest X-Ray), mesentery,
and porta hepatis 3.9 × 7 cm in AP and transverse dimension
in the mesentery and 4 × 5 cm AP and transverse dimension
at the porta hepatis (CT abdomen).
Tests conducted in the ID clinic as workup for “pyrexia
of unknown origin” were negative for malaria, typhoid
(blood and bonemarrow culture), malignancy (bonemarrow
smear and trephine results showing normal erythropoiesis,
myelopoiesis, andmegakaryocytes), and autoimmunedisease
(negative dsDNA, rheumatoid factor, and Coombs test).
A chest X-ray and abdominal ultrasound were repeated
to monitor size of lymph nodes after 2 months of ATT. They
remained as before. Tissue diagnosis was stressed on and a
CT-guided mesenteric lymph node biopsy was carried out
and sent for histopathology and an AFB culture, keeping our
top differentials ofmalignancy andmultidrug resistant tuber-
culosis (MDR-TB) in mind. Fungal and bacterial cultures
could not be sent due to inadequate tissue.
Histopathology sections revealed extensive necrosis with
aggregates of epithelioid histiocytes forming granulomas in
the core tissue (see arrow in Figure 1). Few Langhans-type
giant cells were also seen. Periodic acid-Schiff (PAS) stain
showed yeasts (see Figure 2) and capsules stained blue with
Alcian blue (arrow Figure 3) suggesting C. neoformans.
Additional tests done after the biopsy result revealed a
very high cryptococcal antigen titre (>1 : 1024) and a negative
HIV antibody. Though the underlying T-cell deficiency was
considered, quantitative evaluation (flow cytometry) was
deferred because of the absence of a clinical history suggest-
ing immune compromise and also because cryptococcosis
is not exclusively an immunocompromised-host disease.
Figure 2: PAS stain of mesenteric lymph node biopsy showing
yeasts, 1000x.
Figure 3: PAS stain with Alcian blue, 1000x.
Theparents refused lumbar puncture because of scepticismof
occult CNSdisease in the absence of signs and symptoms.The
childwas assumed to have high antigenemiawith lymphnode
involvement and unknown CNS status. Amphotericin was
started at a dose of 0.5mg/kg/day and increased over 2-3 days
to 1.5mg/kg/day. Flucytosine, recommended by the IDSA
in conjunction with amphotericin for cryptococcosis, was
not available in Karachi. The child was ultimately discharged
home on oral fluconazole monotherapy (6mg/kg/day) as the
parents were reluctant to administer prolonged parenteral
amphotericin at home.
At one-month follow-up, the patient had gained 2 kg, had
defervesced, and resumed normal home and school activities.
At 3 months, she was clinically well with improvement in
lymph node size on abdominal ultrasound and chest X-
ray. Therapy was monitored by repeat cryptococcal antigen
titres which progressively decreased over 6months of therapy
(more than 1 : 1024 during admission, 1 : 1024 one month,
1 : 256 three months, and 1 : 32 five months of therapy). The
family did not return to our center for a follow-up or immune
workup beyond 6 months. The patient is doing well after
cessation of therapy and continues to thrive as per telephonic
contact with parents.
3. Discussion
Pathogenesis of cryptococcosis in “phenotypically normal”
hosts like our patient, without predisposing factors such as
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HIV, transplant, clinical history suggesting T-cell immunode-
ficiency, or chronic conditions such as end-stage liver disease
and renal insufficiency, has been studied [4]. It involves innate
(macrophages, complement andNatural Killer) (NK) defense
mechanisms, and cell-mediated (CD4 cells) and humoral
immunity (facilitation of phagocytosis) [6]. Pathogen factors
such as the capsule and host factors such as surfactant at the
alveolar level have been implicated in helping the organism
evade detection bymacrophages. Although precisely how the
human host controls cryptococci remains unclear, clinical
practice suggests that immunosuppressive agents like corti-
costeroids allow cryptococci to reactivate, CD4 cell numbers
are critically important to host immunity, and cryptococcal
proliferation in humans is clearly contained by a vigorous
granulomatous response [7, 8]. Cryptococcosis should there-
fore be considered as a differential in the workup for PUO,
especially in the presence of granulomatous inflammation.
Our patient had an uneventful first 5 years of life till
the onset of this illness. Changing trends in epidemiology
of cryptococcosis in China shows that the majority of
cases occurred in a non-HIV, nontransplant “phenotypically
normal” cohort [5]. Kiertiburanakul et al. in a retrospective
review (1987–2003) of HIV-negative patients with positive
cryptococcal cultures showed that 35% patients had no
underlying conditions [9]. Idiopathic CD4 lymphocytope-
nia (ICL) was found in 11 patients with cryptococcosis
reviewed over a 12-month period with features similar to
those of cryptococcal infections in normal hosts [10]. Our
threshold for suspecting immunodeficiency was very high.
Ideally quantitative deficiencies, especially in the absence
of the availability of qualitative immune tests in Karachi,
would have been useful in deciding on the drug of choice,
duration of treatment, and prognostication. The family was
retrospectively counseled to get an immune workup in case
of prolonged or unusual fever.
CNS is the commonest system affected in cryptococco-
sis [3]. Occult disease can occur without overt signs and
symptoms. Though the parents refused a lumbar puncture,
they were extensively counseled that this would mean a
longer course of therapy and difficulty in prognostication.
Pulmonary involvement has been reported in 10–36%of non-
HIV patients [11]. Symptoms can be absent in up to one-
third of the patients with abnormal X-rays. Our child had no
pulmonary symptoms: her chest X-ray showed normal lung
fields and hilar lymphadenopathy.
Tissue-based PCR is the gold standard for diagnosis on
histopathology [12]. This was not done as it was unavailable
in our institution. Liaw et al. report direct determination of
cryptococcal antigen through latex agglutination system in
transthoracic needle lung aspirate with a positive predictive
value of 89% and a negative predictive value of 100% [13].
Fridlington et al. have also reported using Tzanck smear on
skin biopsy which revealed narrow-based budding encapsu-
lated yeasts, suggesting cryptococcosis, and was confirmed
by fungal culture [14]. These may have additive value in the
absence of tissue-PCR and fungal culture.
Cryptococcal lymphadenopathy has been reported in
HIV and immunocompetent patients with some and appar-
ently no immune deficiency [1, 15–17]. Karagu¨zel reported
a child with mesenteric cryptococcal lymphadenitis who
presented with acute abdomen [18].
Wu et al. reported on a 10-year-old boy with disseminated
cryptococcosis resembling lymphoreticular malignancy [19].
Differentials of granulomatous inflammation on biopsy in
countries like Pakistan should include cryptococcosis.
IDSA guidelines recommend that cryptococcemia or
dissemination (involvement of at least 2 noncontiguous sites
or evidence of high fungal burden based on cryptococcal
antigen titer 1 : 512), as in our case, should be treated as
CNS disease (2 weeks of induction therapy with IV ampho-
tericin with flucytosine, followed by 8 weeks of maintenance
therapy with oral fluconazole) [20]. Our patient received
IV amphotericin while in hospital (approximately 3 days
between histopathology reporting and discharge).The family
refused parenteral therapy even though they were coun-
seled about the drug of choice in the absence of ruling
out CNS involvement. The patient was sent home on oral
fluconazole therapy for 6–12 months with instructions to
have cryptococcal antigen titre repeated every 2 months. She
remained lost to follow-up for almost two years after 6-month
therapy until the parents contacted the primary physician.
The child remains well and asymptomatic to date. Induction
with fluconazole has been recommended only for patients
with no antigenemia and no CNS disease and only single
site involvement. Our patient had very high antigenemia and
lymphadenopathy (mesenteric and porta hepatis, the latter
causing secondary cholestasis).
Heteroresistance and emerging resistance have been
implicated as possible causes in reactivation of cryptococcosis
in patients treated with fluconazole in induction phase [21].
We were relatively successful in monitoring therapy suc-
cess with the help of progressively falling antigen titres over
6 months of therapy. However, patients like these should be
ideally followed posttreatment and investigated for immune
deficiency.
We should also send tissue for fungal and AFB cul-
tures in addition to bacterial cultures when faced with
lymphadenopathy and Fever of Unknown Origin, or empiric
ATT failures.
4. Conclusion
Cryptococcosis should be considered as a differential of Fever
of Unknown Origin and granulomatous lymphadenopathy
in Pakistan. Patients should be investigated for immunodefi-
ciency, and extent of disease should be established. Clinical
suspicion must be communicated at the time of sending
specimens to the laboratory so that optimal diagnostic tools
can be resourced.
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